About This Site

About EBC-46 Research Hub

EBC-46 Research Hub is an independent science publication tracking the clinical development of tigilanol tiglate (EBC-46) — a naturally occurring compound isolated from the seeds of the Blushwood tree (Fontainea picrosperma), native to the Far North Queensland rainforest in Australia. This site covers the full research landscape: from oncology clinical trials to consumer-reported supplement experiences.

We cover the full arc of EBC-46’s scientific journey: from its discovery at QIMR Berghofer Medical Research Institute, through veterinary FDA approval as Stelfonta®, to ongoing Phase I/II human clinical trials — and the growing body of consumer supplement reports on energy, immune support, inflammation, and skin health. Every clinical claim is grounded in primary sources: published literature, regulatory filings, and registered trial data.

About the Author

My name is Marcus Webb. I’m a science writer and independent researcher with a background in natural compound pharmacology and translational oncology. I have been tracking the clinical development of EBC-46 since 2019, when Phase I human data first demonstrated meaningful complete response rates at injected tumour sites.

Before writing independently, I worked in science communication for academic medical centres, developing a focus on novel oncology agents moving through the regulatory pipeline. EBC-46 caught my attention because it represents something rare in cancer research: a plant-derived compound that has cleared the bar of rigorous Phase I human trials and secured regulatory approval in two major jurisdictions — all within a decade of initial discovery.

Beyond the clinical pipeline, I closely follow the expanding consumer supplement market around Blushwood berry extract. While no peer-reviewed clinical research on oral intake of the natural extract currently exists, a significant and growing volume of consumer-reported experiences — covering energy, inflammation, immune support, and skin health — makes this an important area to track and document accurately.

What We Cover

• EBC-46 mechanism of action — PKC activation, tumour vascular disruption, and immune-mediated clearance
• Clinical trial data — Phase I and II results, response rates, dosing, and safety profiles
• Regulatory milestones — FDA and EMA approvals, Orphan Drug Designation, and what each means for the human development pathway
• Blushwood berry extract science — phytochemistry, extraction methods, and naturally occurring tigilanol tiglate
• Comparative oncology — how EBC-46’s intratumoral approach compares to immunotherapy and conventional chemotherapy
• Research updates — new studies, trial registrations, and developments from QBiotics Group and QIMR Berghofer
• Energy & vitality — consumer reports of improved energy levels and general vitality from oral Blushwood berry extract supplements
• Inflammation — consumer accounts of reduced chronic inflammation, joint comfort, and improved mobility from supplement use
• Immune support — user-reported improvements in immune system function and general resilience among Blushwood berry extract supplement users
• Skin health — both topical and internal consumer reports covering skin clarity, mole changes, and skin-related effects of Blushwood berry extract
• Blushwood berry extract supplements — tracking the consumer supplement market, reader-reported experiences, and customer testimonials. Important note: no peer-reviewed clinical research on oral intake currently exists; this coverage is observational and consumer-reported

A Note on Supplement Coverage

The clinical and supplement sides of EBC-46 research are distinct but connected. Pharmaceutical-grade tigilanol tiglate (Stelfonta®) is rigorously tested and regulatory-approved. Oral Blushwood berry extract supplements are a separate category entirely — and no peer-reviewed clinical research on their oral use currently exists.

When covering supplement user experiences, this site clearly labels them as consumer-reported observations, not clinical evidence. We document what people report, note the absence of controlled research, and encourage readers to consult healthcare professionals before using any supplement. Accuracy and intellectual honesty are non-negotiable.

Editorial Standards

Every clinical claim published on this site is supported by a citation to primary sources: peer-reviewed journals, regulatory documents (FDA, EMA), or data from registered clinical trials. We clearly distinguish between preclinical data, veterinary clinical data, and human clinical data. This distinction matters enormously — a finding in mice does not automatically translate to humans.

This site has no affiliation with QBiotics Group, any pharmaceutical company, or healthcare provider. It receives no industry funding. All editorial decisions are made independently.